title: [Metabolic activity of neutrophilic granulocytes and possible ways of its correction in patients with acute coronary syndrome].
abstract: The present study aimed to investigate the metabolic activity of neutrocytes and the action of corvitin on the level of superoxide anion and myeloperoxidases of cells in vitro with the calculation of index of consumption of myeloperoxidase in patients with ST-elevation acute coronary syndrome. Patient were divided into 2 groups according to the level of superoxide anion. Group 1 included the patients (68%) with the initially low level of superoxide anion, and adding of corvitin to the cells of such patients promoted normalization of this index. In this group we observed also neutrocytosis, low index of consumption of myeloperoxidase and a high level of this enzyme in general population of neutrocytes. Group 2 included patients (32%) with initially normal level of superoxide anion. In this group, corvitin did not influence substantially this factor. Such patients had a level ofmyeloperoxidase within control values and the index of consumption of this enzyme was also within control values. The analysis of hospital period showed that the patients of group 1 had a higher frequency of ventricular tachycardia/ventricular fibrillation, paroxysms of atrial fibrillation, bundle-branch blocks and worsening of the kidney function. We suppose that a low level of superoxide anion in neutrocytes play a major role in the development of complications in patients with acute coronary syndrome. An intravenous administration of corvitin was effective in restoring the metabolic activity of neutrocytes.
authors.forename: N A
authors.initials: NA
authors.lastname: Ryzhkova
authors.forename: T I
authors.initials: TI
authors.lastname: Havrylenko
authors.forename: O M
authors.initials: OM
authors.lastname: Parkhomenko
authors.forename: S M
authors.initials: SM
authors.lastname: Kozhukhov
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism; D011794:Quercetin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013481:Superoxides / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D013481:Superoxides; D011794:Quercetin; D009195:Peroxidase